Enspryng 120 mg
As listed in the register: Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung
120 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Satralizumabum
- Made by
- Roche Pharma (Schweiz) AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Behandlung von Erwachsenen und Jugendlichen mit Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD)
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Roche Pharma (Schweiz) AG |
|---|---|
| Active substance | Satralizumabum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 120 mg |
| Classification | L04AC19 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung |
| Packs | 1 Fertigspritze(n) |
| Zulassungsnummer | 67617 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.